SONX vs. BIOL, XBIO, MYMD, NIVF, LIXT, HILS, SHPH, ENVB, TFFP, and ADIL
Should you be buying Sonendo stock or one of its competitors? The main competitors of Sonendo include BIOLASE (BIOL), Xenetic Biosciences (XBIO), MyMD Pharmaceuticals (MYMD), NewGenIvf Group (NIVF), Lixte Biotechnology (LIXT), Hillstream BioPharma (HILS), Shuttle Pharmaceuticals (SHPH), Enveric Biosciences (ENVB), TFF Pharmaceuticals (TFFP), and Adial Pharmaceuticals (ADIL). These companies are all part of the "medical" sector.
BIOLASE (NASDAQ:BIOL) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking.
BIOLASE currently has a consensus price target of $77.00, suggesting a potential upside of 45,220.78%. Sonendo has a consensus price target of $1.88, suggesting a potential upside of 1,776.88%. Given Sonendo's higher probable upside, equities analysts plainly believe BIOLASE is more favorable than Sonendo.
BIOLASE has a net margin of -41.97% compared to BIOLASE's net margin of -138.88%. BIOLASE's return on equity of -121.92% beat Sonendo's return on equity.
BIOLASE received 277 more outperform votes than Sonendo when rated by MarketBeat users. Likewise, 55.38% of users gave BIOLASE an outperform vote while only 40.74% of users gave Sonendo an outperform vote.
BIOLASE has higher revenue and earnings than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.
BIOLASE has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Sonendo has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
In the previous week, BIOLASE had 2 more articles in the media than Sonendo. MarketBeat recorded 2 mentions for BIOLASE and 0 mentions for Sonendo. Sonendo's average media sentiment score of 0.01 beat BIOLASE's score of 0.00 indicating that BIOLASE is being referred to more favorably in the media.
8.8% of BIOLASE shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 0.0% of BIOLASE shares are held by company insiders. Comparatively, 6.4% of Sonendo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
BIOLASE beats Sonendo on 10 of the 17 factors compared between the two stocks.
Get Sonendo News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SONX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
